Mifomet

Metformin Hydrochloride and Sitagliptin, the active ingredients in Mifomet, are a combination of a biguanide and a DPP‑4 inhibitor presented as tablets for oral use. It treats type 2 diabetes mellitus in adults when diet and exercise alone are insufficient.

GNH USA supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifomet, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves overall glycemic control and reduces HbA1c levels. - Patients inadequately controlled on metformin alone: adds DPP‑4 inhibition for additional glucose lowering. - Adults requiring combination therapy: simplifies regimen by combining two agents in one tablet.

Mifomet may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycemia: especially when used with other glucose‑lowering agents. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening condition linked to metformin. - Severe hypoglycemia: can occur with concomitant sulfonylureas. - Pancreatitis: inflammation of the pancreas associated with sitagliptin. - Allergic reactions: rash, pruritus, or angioedema. - Hepatic failure: rare liver dysfunction requiring immediate medical attention.

Before prescribing Mifomet, clinicians should consider several safety factors.

- Renal function: assess eGFR and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal impairment. - Hepatic disease: use with caution in patients with liver dysfunction. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Known hypersensitivity: contraindicated in patients allergic to metformin or sitagliptin. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mifomet can interact with various medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): metformin accumulation risk. - MAO inhibitors: increased risk of hypoglycemia. - Strong CYP3A4 inhibitors: may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Sulfonylureas: additive hypoglycemia risk. - Thiazolidinediones: enhanced glucose‑lowering effect. - Iodinated contrast media: transient renal function decline affecting metformin clearance.